Abstract Number: 2481 • ACR Convergence 2024
General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Background/Purpose: The most common types of ANCA-associated vasculitis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), can affect a range of organs, including the kidneys,…Abstract Number: 0311 • ACR Convergence 2024
Investigation of Sarcoidosis-associated Neuropathy: Challenges with Diagnosis of Small Fiber Neuropathy
Background/Purpose: Small fiber neuropathy (SFN) is an underrecognized complication of sarcoidosis which can significantly impair individuals’ physical functioning and quality of life. Diagnosis includes both…Abstract Number: PP09 • ACR Convergence 2024
Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS
Background/Purpose: Like many suffering from autoimmune diseases, my diagnosis was not straightforward and took nearly 13 years to get answers. I first started experiencing an…Abstract Number: 0312 • ACR Convergence 2024
The Use of Electromyography as a Screening Tool in Sarcoidosis-associated Neuropathy
Background/Purpose: Small fiber neuropathy (SFN) is the most common peripheral nervous system manifestation of sarcoidosis. Diagnosis of SFN includes clinical evaluation, occasionally skin biopsy to…Abstract Number: 0363 • ACR Convergence 2024
Comparative Risk of Demyelinating Diseases Among Patients on TNF-Alpha Inhibitors: A Cohort Study Using the TriNetX Database
Background/Purpose: TNF-alpha inhibitors are widely used in the field of rheumatology and have been linked to various possible adverse events, including demyelinating diseases. This association…Abstract Number: 0844 • ACR Convergence 2024
Effectiveness and Safety of the Recombinant Zoster Vaccine in Patients ≥18 Years of Age with Systemic Lupus Erythematosus or Multiple Sclerosis
Background/Purpose: The recombinant zoster vaccine (RZV) is US Food and Drug Administration-approved for the prevention of herpes zoster (HZ, shingles) in adults ≥50 years, and…Abstract Number: 0926 • ACR Convergence 2024
Macrophages and Nociceptor Neurons Form a Sentinel Unit Around Fenestrated Capillaries to Defend the Synovium from Systemic Challenges
Background/Purpose: A wide variety of systemic pathologies, including infectious and autoimmune diseases, are accompanied by joint pain or inflammation, often mediated by circulating immune complexes…Abstract Number: 1092 • ACR Convergence 2024
Chronic Kidney Disease Is Associated with Increased Glucose Uptake-associated Metabolic Activity of Visceral Adipose and Subcutaneous Adipose Tissue in Gout Patients
Background/Purpose: Gout, a condition characterized by elevated uric acid levels, is linked to multiple complications, including coronary artery disease, hypertension, and type 2 diabetes mellitus.…Abstract Number: 1093 • ACR Convergence 2024
Risk of Dementia in Patients with Gout: Potential Impact of Survival Bias
Background/Purpose: Prior studies reported a lower risk of dementia among patients with gout suggesting that hyperuricemia might play a neuroprotective role. However, risk estimates for…Abstract Number: 1164 • ACR Convergence 2024
IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients
Background/Purpose: Immune Mediated Necrotizing Myopathy (IMNM) is a debilitating but understudied entity. Correlations of demographic and clinical features with pathological findings remain underexplored. In addition,…Abstract Number: 1227 • ACR Convergence 2024
Longitudinal Patterns of Fibromyalgia Phenotypes in Patients with Systemic Lupus Erythematosus
Background/Purpose: Fibromyalgia (FM) is a common comorbidity in patients with systemic lupus erythematosus (SLE) and a major contributor to poor health related quality of life.…Abstract Number: 1276 • ACR Convergence 2024
Therapeutic Drug Monitoring (TDM) of Rituximab to Predict Early B-Cell Repopulation in Children
Background/Purpose: Rituximab is increasingly used in pediatric inflammatory diseases, with dosing extrapolated from adult data due to a lack of pediatric-specific pharmacokinetic (PK) information. Children…Abstract Number: 1414 • ACR Convergence 2024
Evidence-Based Guidelines for Sjögren’s Disease Peripheral Nervous System Manifestations
Background/Purpose: Peripheral Nervous System (PNS) manifestations occur frequently in Sjögren’s disease and can encompass mononeuropathy, polyneuropathy, and autonomic neuropathy. Guidance is needed for rheumatologists, neurologists,…Abstract Number: 1420 • ACR Convergence 2024
Alignment Between Rheumatology and Neurology of Nomenclature for Peripheral Nervous System Neuropathies
Background/Purpose: The Sjögren’s Foundation Clinical Practice Guidelines for Peripheral Nervous System (PNS) diagnosis, management and treatment in Sjögren’s brought to the fore a major issue…Abstract Number: 2177 • ACR Convergence 2024
CD59 Complement Membrane Regulator Deficiency: 12 Years of Clinical and Molecular Follow-up of 29 Patients
Background/Purpose: We have described in 2013, homozygous CD59-deficient children that manifest with recurrent peripheral neuropathy resembling Guillain-Barré syndrome (GBS), with hemolytic anemia and recurrent strokes.…
- 1
- 2
- 3
- 4
- Next Page »